This cluster aims to encourage collaborations between members of the School involved in various aspects of applied drug discovery, and to enhance research links with the wider biomedicine community.
The Drug Discovery Cluster aims to participate in all the stages of early phase drug discovery from chemical biology approaches to new target identification and validation through to the nomination of quality clinical drug candidates to treat human disease of high unmet medical need (e.g. cancer, infection, neurodegenerative disease).
Our work is interdisciplinary, ranging from medicinal and synthetic chemistry to pharmacology, structural biology, proteomics, microbiology and phytomedicines.
The Drug Discovery and Therapeutic Target Identification Cluster is closely aligned with the UCL Translational Research Office which aims to facilitate the translation of basic and clinical research.
- Geoff Wells (Cluster Lead)
- Duncan Browne, Browne Research Group
- Rachael Dickman
- Shozeb Haider
- Michael Heinrich, Google Scholar link, LinkedIn contact
- Stephen Hilton, Stephen Hilton website
- Frank Kozielski
- Rebecca Lever
- John Malkinson
- Mike Munday
- Stephen Neidle
- Gary Parkinson
- Arnaud Ruiz
- Andreas Schatzlein
- Rosemary Smyth
- Paul Stapleton
- Mat Todd, The Todd Group
- Zoe Waller
- Andy Wilderspin
- Esther Woon, Google Scholar link